Prevent Infusion-Related Reactions With Intravenous Amivantamab: Primary Results From SKIPPirr, a Phase 2 Study

Panelists discuss how amivantamab, FDA approved for first-line treatment of advanced non–small cell lung cancer with specific EGFR mutations, can lead to significant infusion-related reactions, including serious cases that may require dose adjustments or discontinuation.

Panelists discuss the frequency, timing, and symptoms of infusion-related reactions with amivantamab plus lazertinib, how these drugs compare with other treatments such as datopotamab deruxtecan (DXd) or patritumab DXd (HER3-DXd), and the management strategies and prophylactic measures used, especially for patients with EGFR exon 19 or L858R advanced/metastatic non–small cell lung cancer who have experienced progression on prior therapies.

Panelists discuss the clinical implications of the SKIPPirr trial data presented at the 2024 World Congress on Lung Cancer, including whether it might reduce resistance to using this combination in practice, how to implement supportive measures such as prophylactic dexamethasone 8 mg, potential barriers to implementation, strategies to overcome these barriers, and ways to educate patients about infusion-related reactions and the benefits of prophylactic measures.

Panelists discuss other adverse events associated with amivantamab and lazertinib beyond infusion-related reactions.

Panelists discuss key takeaways from the analysis and offer clinical pearls on incorporating prophylactic dexamethasone 8 mg into treatment with amivantamab and lazertinib for community colleagues.